Monsanto to sales and distribution facilities in 51 countries. In 2005, it finalized the purchase of Seminis Inc, a leading global vegetable and fruit seed company, for $1.4 billion. This made it the world's largest conventional seed company. In 1999 Monsanto sold off NutraSweet Co. In December of the same year, Monsanto agreed to merge with Pharmacia & Upjohn, in a deal valuing the transaction at $27 billion. The agricultural division became a wholly owned subsidiary of the "new" Pharmacia; Monsanto's medical research division, which included products such as Celebrex. In 2000: Pharmacia spun off its agro-biotech subsidiary into a new
Monsanto process as catalysts. Because acetic anhydride hydrolyzes, the conversion is conducted under anhydrous conditions in contrast to the Monsanto acetic acid synthesis. Monsanto process The Monsanto process is an industrial method for the manufacture of acetic acid by catalytic carbonylation of methanol. The Monsanto process has largely been supplanted by the Cativa process, a similar iridium-based process developed by BP Chemicals Ltd which is more economical and environmentally friendly. This process operates at a pressure of 30–60 atm and a temperature of 150–200 °C and gives a selectivity greater than 99%. It was developed in 1960 by the German chemical company,